<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416311</url>
  </required_header>
  <id_info>
    <org_study_id>114877</org_study_id>
    <secondary_id>CETB115B1401</secondary_id>
    <nct_id>NCT01416311</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation for REVOLADE (ITP)</brief_title>
  <official_title>Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects&#xD;
      receiving the drug until data from a specified number of subjects are accumulated to identify&#xD;
      factors considered to influence its safety and efficacy.&#xD;
&#xD;
      &lt;Priority investigation item&gt; Thromboembolism&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2010</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 16, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with any adverse events treated with REVOLADE</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appearance of thromboembolism</measure>
    <time_frame>1 year</time_frame>
    <description>If thromboembolism is appeared or not in subjects who received REVOLADE will be investigated throughout the study period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5797</enrollment>
  <condition>Purpura, Thrombocytopaenic, Idiopathic</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed REVOLADE</arm_group_label>
    <description>Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <arm_group_label>Subjects prescribed REVOLADE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All Japanese subjects with chronic idiopathic thrombocytopenic purpura who recieve REVOLADE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic idiopathic thrombocytopenic purpura&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

